HUP0202534A2 - Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0202534A2
HUP0202534A2 HU0202534A HUP0202534A HUP0202534A2 HU P0202534 A2 HUP0202534 A2 HU P0202534A2 HU 0202534 A HU0202534 A HU 0202534A HU P0202534 A HUP0202534 A HU P0202534A HU P0202534 A2 HUP0202534 A2 HU P0202534A2
Authority
HU
Hungary
Prior art keywords
group
compounds
inter alia
agonists
formula
Prior art date
Application number
HU0202534A
Other languages
English (en)
Inventor
Pamela Albaugh
Alan Hutchison
Kenneth Shaw
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of HUP0202534A2 publication Critical patent/HUP0202534A2/hu
Publication of HUP0202534A3 publication Critical patent/HUP0202534A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047Benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A találmány helyettesített pirrol-karboxamid vegyületeket ismertet. Atalálmány tárgyát képezik a (I) általános képletű vegyületek vagy azokgyógyászatilag elfogadható sói - a képletben T jelentése - többekközött - hidrogénatom; X jelentése - többek között - hidroxil- vagyalkoxicsoport; G jelentése az (1) képletű csoport, ahol Q jelentése -többek között - aril- vagy adott esetben helyettesítettheteroarilcsoport; W jelentése - többek között - -O-, -NH- vagy CR7R8-csoport; Z jelentése - többek között - hidroxilcsoport, R3, R4, R5 ésR6 azonos vagy különböző, és jelentése - többek között - hidrogénatomvagy N-alkil-piperazinil-csoport. E vegyületek szelektív agonisták,antagonisták vagy inverz agonisták a GABAA-agyreceptorokra vagy aGABAA-agyreceptorok agonistái, antagonistái, vagy inverz antagonistáiprodrugjai, és ezért alkalmazhatók idegesség, depresszió, Alzheimer-féle dementia, alvási és kényszeres rendellenességek, benzodiazepinhatóanyagok túladagolása kezelésében és a memória fokozásában. Atalálmány tárgyát képezik továbbá gyógyászati készítmények, ezen belülkiszerelt gyógyászati készítmények. A találmány szerinti vegyületektovábbá alkalmazhatók próbavegyületekként szövetmintákban GABAA-receptorok lokalizálására. Ó
HU0202534A 1999-08-31 2000-08-30 Fused pyrrolecarboxamides: gaba brain receptor ligands and pharmaceutical compositions containing them HUP0202534A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15178999P 1999-08-31 1999-08-31
US38731199A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
HUP0202534A2 true HUP0202534A2 (hu) 2002-11-28
HUP0202534A3 HUP0202534A3 (en) 2002-12-28

Family

ID=26848974

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202534A HUP0202534A3 (en) 1999-08-31 2000-08-30 Fused pyrrolecarboxamides: gaba brain receptor ligands and pharmaceutical compositions containing them

Country Status (25)

Country Link
US (1) US7109351B1 (hu)
EP (1) EP1210328A1 (hu)
JP (1) JP2003508385A (hu)
KR (1) KR20020027613A (hu)
CN (1) CN1372546A (hu)
AP (1) AP2002002420A0 (hu)
AU (1) AU7092800A (hu)
BG (1) BG106459A (hu)
BR (1) BR0013664A (hu)
CA (1) CA2381553A1 (hu)
CR (1) CR6581A (hu)
CZ (1) CZ2002614A3 (hu)
EA (1) EA200200188A1 (hu)
EE (1) EE200200111A (hu)
HR (1) HRP20020104A2 (hu)
HU (1) HUP0202534A3 (hu)
IL (1) IL147971A0 (hu)
IS (1) IS6290A (hu)
MX (1) MXPA02001709A (hu)
NO (1) NO20020948L (hu)
OA (1) OA12015A (hu)
PL (1) PL354513A1 (hu)
SK (1) SK2582002A3 (hu)
TR (1) TR200200544T2 (hu)
WO (1) WO2001016103A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
AU2001241512A1 (en) * 2000-03-13 2001-09-24 Eli Lilly And Company Sulfonamide derivatives
US6723332B2 (en) 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
MXPA03001945A (es) * 2000-09-06 2003-09-10 Neurogen Corp Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a.
WO2002020480A1 (en) * 2000-09-06 2002-03-14 Neurogen Corporation Substituted fused pyrroleimines and pyrazoleimines
US6861529B2 (en) 2001-07-06 2005-03-01 Pfizer Inc Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
US6852730B2 (en) 2002-02-07 2005-02-08 Neurogen Corporation Substituted fused pyrazolecarboxylic acid arylamides and related compounds
AU2004265189B2 (en) * 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ,エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
US20080275112A1 (en) * 2004-07-23 2008-11-06 Schreiner Peter R Invention Concerning Aminoadamantane Compounds
MY150731A (en) * 2006-11-27 2014-02-28 Lundbeck & Co As H Heteroaryl amide derivatives
JP2011506445A (ja) * 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455943A (en) 1966-10-21 1969-07-15 American Cyanamid Co Certain 5,8-dihydro-beta-carbolines
US4075343A (en) 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
DE3029980A1 (de) 1980-08-08 1982-03-11 Boehringer Mannheim Gmbh, 6800 Mannheim Indolderivate und verfahren zu ihrer herstellung
JPS57123180A (en) 1980-12-17 1982-07-31 Schering Ag 3-substituted beta-carboline, manufacture and psychotropic drug containing same
DE3147276A1 (de) 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
DE3246932A1 (de) 1982-12-16 1984-06-20 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte 5h-pyrimido(5,4-b)indole
DE3335323A1 (de) 1983-09-27 1985-04-04 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte ss-carboline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8429739D0 (en) 1984-11-24 1985-01-03 Fbc Ltd Fungicides
DE3535927A1 (de) 1985-10-04 1987-04-09 Schering Ag 3-vinyl- und 3-ethinyl-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
DK0552237T3 (da) 1990-10-09 1993-07-28 Neurogen Corp Visse cycloalkyl- og azacycloalkyl-pyrrolopyrimidiner, en klasse af ligander for GABA-receptorer i hjernen
US5243049A (en) 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
EP0626966A1 (en) 1992-02-19 1994-12-07 PHARMACIA & UPJOHN COMPANY 3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
AU6098194A (en) 1993-01-29 1994-08-15 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US6211365B1 (en) * 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US5804686A (en) * 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
IT1287264B1 (it) * 1996-03-21 1998-08-04 Lino Crespan Freno perfezionato per pattini con ruote in linea
US5955465A (en) 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
WO1997034870A1 (en) * 1996-03-22 1997-09-25 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5677309A (en) 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
EA002243B1 (ru) * 1997-11-13 2002-02-28 Пфайзер Продактс Инк. Способ синтеза пирроламидов

Also Published As

Publication number Publication date
IL147971A0 (en) 2002-09-12
HUP0202534A3 (en) 2002-12-28
CR6581A (es) 2004-03-31
WO2001016103A1 (en) 2001-03-08
MXPA02001709A (es) 2002-10-23
BR0013664A (pt) 2002-05-14
NO20020948D0 (no) 2002-02-27
EP1210328A1 (en) 2002-06-05
KR20020027613A (ko) 2002-04-13
SK2582002A3 (en) 2003-02-04
BG106459A (bg) 2002-12-29
IS6290A (is) 2002-02-27
HRP20020104A2 (en) 2004-02-29
CN1372546A (zh) 2002-10-02
EA200200188A1 (ru) 2002-08-29
CZ2002614A3 (cs) 2002-08-14
CA2381553A1 (en) 2001-03-08
TR200200544T2 (tr) 2002-06-21
NO20020948L (no) 2002-02-28
AU7092800A (en) 2001-03-26
JP2003508385A (ja) 2003-03-04
US7109351B1 (en) 2006-09-19
AP2002002420A0 (en) 2002-03-31
EE200200111A (et) 2003-06-16
OA12015A (en) 2006-04-19
PL354513A1 (en) 2004-01-26

Similar Documents

Publication Publication Date Title
HUP0202534A2 (hu) Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények
AU4818000A (en) Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
GEP20033025B (en) 4,4-Biarylpiperidine Derivatives with Opioid Receptor Activity
HUP9901199A2 (hu) Neurotranszmitter újrafelvételt gátló tropánszármazékok és eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
DE60232029D1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
MXPA03001344A (es) Derivados de piridina 2,4-substituidos.
ATE347553T1 (de) Amino-substituierte pyrazolo 1,5-aö-1,5- pyrimidine und pyrazolo 1,5-aö-1,3,5-triazine
PH31335A (en) Naphthalamides as central nervous system agent.
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
NO20020282D0 (no) Nytt difenylpiperidinderivat
PT757685E (pt) Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
AU2342397A (en) N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
TNSN00105A1 (fr) Derives de 1-trifluoromethyl-4-hydroxy-7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
HUP0004671A2 (hu) 5-Szubsztituált-3-oxadiazolil-1,6-naftiridin-2(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények
TNSN00095A1 (fr) Benzolactames et thioamides cycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
NO20016255L (no) Kromeno[4,3,2-de]isoquinoline som potente dopamineresepter ligander
TNSN00178A1 (en) Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands